← Search & browse all drugs
CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › HMG CoA reductase inhibitors
rosuvastatin
C10AA07
Forms & Strengths
- Tablets: 5mg, 10mg, 20mg, 40mg
- film-coated
Adult Dosing
- Hyperlipidemia: 5-40mg orally once daily
- Start with 10mg/day, adjust at 2-4 week intervals
- Maximum dose: 40mg/day
Pediatric Dosing
- Heterozygous familial hypercholesterolemia: 5-10mg/day for 8-13 years, 5-20mg/day for 14-17 years
- 10-40mg/day for homozygous familial hypercholesterolemia
Indications
- Hyperlipidemia
- Heterozygous and homozygous familial hypercholesterolemia
- Slowing the progression of atherosclerosis
- Primary prevention of cardiovascular disease
Mechanism of Action
- Competitive inhibition of HMG-CoA reductase
- Decreases hepatic cholesterol synthesis and increases LDL receptor expression
Contraindications
- Hypersensitivity to rosuvastatin
- Active liver disease
- Pregnancy and lactation
Adverse Reactions
- Headache
- Myalgia
- Constipation
- Nausea
- Abdominal pain
- Elevated liver enzymes
- Rhabdomyolysis (rare)
Drug Interactions
- Cyclosporine: increases rosuvastatin levels
- Gemfibrozil: increases risk of myopathy
- Antacids: decreases rosuvastatin absorption
- Warfarin: increases INR
Curated Content: Needs Vetting Before Put to Clinical Use